Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long

Antibody Products Will Be An Important Option Until Vaccines Reduce Infections

Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.

Coronavirus
Regeneron has received an EUA for its two-antibody cocktail for SARS-CoV-2 infection. • Source: Shutterstock

Regeneron Pharmaceuticals, Inc.’s two-antibody cocktail for coronavirus infection, REGN-COV2 (casirivimab/imdevimab), will join Eli Lilly and Company’s antibody product, helping to ease the immediate demand for a COVID-19 treatment, but the long-term potential of these antibody treatments remains uncertain as the introduction of vaccines are expected to taper off infections.

On 21 November, Regeneron received an emergency use authorization for casirivimab and imdevimab (previously known as REGN-COV2 or REGEN-COV2) from...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category